Research Article

Assessment of Anticholinesterase Activity of Gelidiella acerosa: Implications for Its Therapeutic Potential against Alzheimer’s Disease

Arif Nisha Syad, Karutha Pandian Shunmugiah, and Pandima Devi Kasi

Department of Biotechnology, Alagappa University, Tamil Nadu, Karaikudi 630 003, India

Correspondence should be addressed to Pandima Devi Kasi, devikasi@yahoo.com

Received 19 August 2012; Revised 8 October 2012; Accepted 25 October 2012

Academic Editor: Andrew Scholey

The effect of various solvent extracts of Gelidiella acerosa on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities was investigated. AChE and BuChE inhibitory activities were analyzed by spectrophotometric method. Phytochemical screening of the compounds present in the solvent extracts was done qualitatively. Characterization of the compounds present in the benzene extract of G. acerosa was done by GC-MS analysis. The results showed that, at 487.80 μg/mL, benzene extract showed significant (P<0.05) inhibitory activity against both AChE and BuChE with the percentage of inhibition 54.18±5.65% (IC50 = 434.61 ± 26.53 μg/mL) and 78.43 ± 0% (IC50 = 163.01 ± 85.35 μg/mL), respectively. The mode of inhibition exhibited by benzene extract against the AChE and BuChE was found to be competitive and uncompetitive type of inhibition, respectively. Preliminary phytochemical analysis coupled with GC-MS illustrates that the benzene extract possesses high amount of terpenoids, which could be the reason for potential cholinesterase inhibitory activity.

1. Introduction

Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the prevalent cause of dementia in elderly population [1]. It is clinically characterized by numerous symptoms such as memory and language impairment, cognitive dysfunction, and behavioral disturbances (i.e., depression, agitation, and psychosis), which become progressively more severe [2]. As the aged population grows, the number of individuals worldwide with AD is expected to rise to 34 million in the next three decades, a dramatic increase from 7.3 million today [3]. This is an alarming prospect, particularly in the absence of effective preventive and therapeutic interventions. The most remarkable biochemical change in AD patients is a reduction of acetylcholine (ACh) levels in the hippocampus and cortex of the brain [4]. Therefore, inhibition of acetylcholinesterase (AChE), the enzyme responsible for hydrolysis of ACh at the cholinergic synapse, is currently the most established approach for treating AD [5]. The clinical efficacy of those AChE inhibitors is thought to result from prolonging the half-life of ACh through inhibition of AChE [6]. Currently, five pharmaceutical drugs representing cholinesterase inhibitors (ChEIs), namely, galantamine, rivastigmine, donepezil, and tacrine, are applied clinically. However they can only offer little more than short-term palliative effects, and moreover these inhibitors suffer from pronounced peripheral side effects [7]. Therefore, there is still a great demand in finding new drug candidates for AD treatment.

Marine resources are the richest source of fauna and flora with untapped potentials. The southern coast of India bears a luxuriant growth of seaweed, and these have been used in Asia for more than 2000 years as a subsidiary food, fertilizers, and animal feed [8]. Recently, edible seaweeds have been shown to exert many positive physiological effects, including antiviral, antitumor, anticancer, hepatoprotective, and antiviral activity [9, 10]. Seaweeds are considered as marine renewable sources and medicinal food of 21st century. The proposed seaweed G. acerosa is a perennial red algae (Rhodophyceae) widely distributed along the south
coastal region, that is, Gulf of Mannar throughout the year. It is widely used in the production of superior quality agar for molecular biology studies and also for the treatment of gastrointestinal disorders [11]. S-ACT-1 a sulfono glycolipid of *G. acerosa* has potent sperm motility stimulating activity *in vitro* [12]. S-PC-1 a sphingosine derivative from *G. acerosa* was found to act as non-steroidal antiprogestone contraceptives [13]. Reports regarding the pharmacological application of *G. acerosa*, especially in the treatment of neurological disorder, are still at its infancy; hence, the objective of our study is to screen for the ChE inhibitory activity of *G. acerosa*, which is commonly available seaweed in southern coast of India. Preliminary screening for antioxidant activity of seaweed has shown that *G. acerosa* extract exhibited excellent antioxidant activity [14]. As the preliminary work was promising, we intended to study the application of this antioxidant seaweed in inhibiting cholinesterase activity so that it could act as safe multipotent drug for treatment of AD.

2. Materials and Methods

2.1. Sample Collection. Seaweed *G. acerosa* was collected along the South Indian coastal area, Tamil Nadu, and the species were identified according to Oza and Zaidu [15] and Krishnamurthy and Joshi [16] and further confirmed by Dr. M. Ganesan, Scientist, CSMCRI, Mandapam Camp, Tamil Nadu, and the voucher specimen was deposited at Department of Biotechnology, Alagappa University, under the accession number AUDBTGA20100101.

2.2. Preparation of Crude Extracts. The seaweeds were washed with alcohol and water and dried under shade. The dried seaweeds were stored in an airtight container, which was stable for at least 12 months. The air dried seaweeds were powdered and successively extracted with different solvents: petroleum ether, hexane, benzene, dichloromethane, chloroform, ethyl acetate, acetone, methanol, and water in Soxhlet apparatus. The extracts were dried under reduced pressure in vacuum dessicator until dryness and the percentage of yield was calculated. The dried extract was dissolved in distilled water containing less than 0.02% of methanol or Tween 20 as solvents and used for further analysis. The yield of the extract was calculated as below:

\[
\text{Yield of the extract} = \frac{\text{Wt. of the beaker with extract} - \text{Wt. of the empty beaker}}{\text{Wt. of the sample in grams}} \times 100. \tag{1}
\]

2.3. Chemicals. Electric eel AChE (Type-VI-S, EC 3.1.1.7, Sigma) and horse serum BuChE (EC 3.1.1.8, Sigma) were used as enzyme source, while acetylthiocholine iodide (ATCI) and butyrylthiocholine iodide (BuTCl) (Himedia laboratories, Mumbai, India) were employed as substrates of the reaction. 5,5'-Dithio-bis(2-nitrobenzoic)acid (DTNB) (Himedia laboratories, Mumbai, India) was used as chromogen for the measurement of the cholinesterase activity. All other chemicals used were of highest purity grade and commercially available.

2.4. Determination of AChE and BuChE Inhibitory Activities. AChE and BuChE inhibitory activities were measured by slightly modifying the spectrophotometric method developed by Ellman et al. [17] and Ingkaninan et al. [18]. Briefly, 10 μL (0.09 U/mL) of AChE/BuChE solution was incubated with 10–50 μL of various concentrations of *G. acerosa* extract (97.56, 195.12, 292.68, 390.24, 487.80 μg/mL) in 0.05 M Tris-HCl buffer (pH 8.0) for 45 min at RT. After incubation, 125 μL of 3 mM DTNB was added, and the total volume was made up to 1 mL with Tris-HCl buffer (pH 8.0). Enzyme activity was initiated with the addition of 25 μL of 15 mM ATCl/BuTCl. The hydrolysis of ATCl and BuTCl was monitored by the formation of yellow 5-thio-2-nitrobenzoate anion as a result of the reaction of DTNB with thiocelolone, catalyzed by the enzyme at a wavelength of 405 nm utilizing UV-Visible spectrophotometer (U-2800, Hitachi, Japan). Percentage of inhibition of AChE/BuChE was determined by comparison of rates of reaction of samples relative to blank sample (Tris-HCl buffer) using the formula \((E - S)/E \times 100\), where *E* is the activity of enzyme without test sample and *S* is the activity of enzyme with test sample. The experiments were done in triplicates. Donepezil (currently employed anticholinesterase drug) was used as standard.

2.5. Phytochemical Analysis. Preliminary phytochemical analysis was carried out on various solvent extracts of *G. acerosa* using standard procedures to identify the constituents as described by Trease and Evans [19], Sofowora [20], and Harborne [21, 22].

2.5.1. Test for Tannins. A few drops of 0.1% ferric chloride were added to the sample and observed for the formation of brownish green or a blue-black coloration.

2.5.2. Test for Flavonoids. About five volumes of dilute ammonia solution were added to a portion of the sample followed by addition of concentrated H₂SO₄. A yellow coloration that was observed indicated the presence of flavonoids. The yellow coloration disappeared on standing.

2.5.3. Test for Terpenoids (Salkowski Test). Five mL of each extract was mixed in 2 mL of chloroform, and concentrated H₂SO₄ (3 mL) was carefully added to form a layer. A reddish brown coloration at the interface was formed to show positive results for the presence of terpenoids.

2.5.4. Test for Cardiac Glycosides (Keller-Kiliiani Test). Five mL of each extract was treated with 2 mL of glacial acetic acid containing one drop of ferric chloride solution. This was underlaid with 1 mL of concentrated sulphuric acid. A brown
ring at the interface indicates a deoxy sugar characteristic of cardenolides. A violet ring may appear below the brown ring, while in the acetic acid layer, a greenish ring may form just gradually throughout thin layer.

2.5.5. **Test for Alkaloids (Dragendorf’s Reagent).** 1.5 mL of 10% HCl was added to about 5 mL of the extract, and the mixture was heated for 20 min. It was cooled and filtered. 1 mL of Dragendorf’s reagent was added. Formation of a reddish or orange colored precipitate indicates the presence of alkaloids [22].

2.6. **Thin Layer Chromatography (TLC) Identification.** Preliminary phytochemical screening was further confirmed by TLC analysis. TLC was performed using Silica gel 60 F254 plates (Merck). For the detection of alkaloids in benzene extract, chloroform/methanol/glacial acetic acid 6 : 1 : 0.1 was used as running solvent, and the plates were detected using Dragendorf’s reagent. In the case of terpenoids, separation of benzene extract was performed using petroleum ether/benzene/dichloromethane 3 : 2 : 5 as running solvents. Plates were visualized by spraying with Vanillin-sulphuric acid reagent, heated at 100°C for 10 min, and then evaluated in visible light [23]. Presence of terpenoids was further confirmed using p-anisaldehyde sulphuric acid as spraying agent using petroleum ether/benzene/dichloromethane 2 : 2 : 6 as running solvents. The color spots detected after spraying with reagents were documented.

2.7. **GC-MS Analysis.** The components of benzene extract were analyzed by GC-MS (GC Clarus 500 Perkin Elmer) instrument with capillary column of Elite-5MS [(5% Diphenyl/95% Dimethyl poly siloxane), 30 × 0.25 mm × 0.25 μm df]. The inlet oven temperature was kept at 110°C initially. The injector temperature was kept at 250°C. 2 μL of sample was injected into GC-MS instrument for analysis. For detection, an electron ionization system with ionization energy of 70 eV was used. Helium was used as carrier gas at flow rate of 1 mL/min. The chemical components of the extract were identified by comparing their retention indices (RI) and mass fragmentation patterns with those on the stored NIST library (National Institute of Standards and Technology).

2.8. **Kinetic Studies.** To evaluate the type of inhibition, in which the extract inhibits the enzyme activity, the parameters $K_m$, $V_{max}$, and $K_t$ values were determined. AChE and BuChE were incubated with different concentrations of benzene extract of *G. acerosa* with increasing substrate concentration, and the assay was performed as mentioned earlier. All the kinetic parameters were calculated by using the software EZ-Fit model (Perella Scientific Inc, USA).

2.9. **Calculation of IC50.** Various concentrations of seaweed extracts were taken for the study, and IC50 value (which shows 50% inhibition) was calculated by probit analysis method.

### Table 1: Percentage of yields (W/W) of different solvent extracts of *Gelidiella acerosa.*

| S. No | Solvent extracts | Yield of extract |
|-------|------------------|------------------|
| 1     | Petroleum ether  | 0.06%            |
| 2     | Hexane           | 0.06%            |
| 3     | Benzene          | 0.06%            |
| 4     | Dichloromethane  | 0.24%            |
| 5     | Chloroform       | 0.06%            |
| 6     | Ethyl acetate    | 0.03%            |
| 7     | Acetone          | 0.41%            |
| 8     | Methanol         | 4.99%            |
| 9     | Water            | 5.01%            |

2.10. **Statistical Analysis.** Experimental results concerning this study were represented as mean ± S.D. of three parallel measurements. Analysis of variance was performed by one-way ANOVA. Significant differences between means were determined by Duncan’s multiple range tests. *P* values <0.05 were regarded as significant and *P* values <0.01 as very significant.

### 3. Results

3.1. **Acetylcholinesterase (AChE) and Butyrylcholinesterase (BuChE) Inhibitory Activity.** The percentage of yield of different solvent extracts of *G. acerosa* is illustrated in Table 1. Various concentrations (97.56–487.80 μg/mL) of different solvent extracts of *G. acerosa* were analyzed for AChE inhibitory activity under *in vitro* condition, and the results are shown in Table 2. Results showed that benzene, ethyl acetate, petroleum ether, chloroform, and acetone showed inhibitory activity against AChE in concentration-dependent manner whereas hexane, dichloromethane, methanol, and aqueous extract showed no activity against AChE. At 487.80 μg/mL benzene and ethyl acetate extract showed significant (*P* < 0.05) inhibitory activity of 54.18 ± 5.65 and 53.57 ± 9.49% when compared to control, but significantly less when compared to standard drug donepezil whose percentage of inhibition is 98.26 ± 2.36% (*IC50* value 5.09 ± 0.004 μg/mL). *IC50* values of benzene and ethyl acetate extract were observed as 434.61 ± 26.53 μg/mL and 444.44 ± 11.63 μg/mL, respectively. Chloroform, acetone, and petroleum ether extract showed moderate inhibitory activity of 37.6 ± 1.17, 45.92 ± 0.679, and 41.36 ± 1.68%, respectively.

In the case of BuChE, at 487.80 μg/mL benzene, chloroform, ethyl acetate, and petroleum ether showed inhibitory activity when compared to control. Hexane, dichloromethane, methanol, and water extracts showed no inhibitory activity against BuChE (Table 3). Of all the extracts benzene and chloroform extract showed significantly (*P* < 0.05) higher inhibition of 78.43 ± 0% and 56.78 ± 2.13% when compared to control with *IC50* values of 163.01 ± 85.35 μg/mL and 375 ± 17.170 μg/mL, respectively. Donepezil, a positive control, showed, significantly higher inhibition of 91.57 ± 2.41% (*IC50* 7.266 ± 0.0065 μg/mL) when compared to seaweed extract. Petroleum ether and
ethyl acetate extract exhibited moderate inhibitory activity of 32.85 ± 4.76 and 37.74 ± 4.19%, respectively. From the above results it is clear that of the entire extracts studied, benzene extract inhibited both AChE and BuChE to greater extent while ethyl acetate extract showed moderate activity against both the ChEs (dual cholinergic effect).

3.2. Phytochemical Screening. Preliminary phytochemical analysis of different solvent extracts of G. acerosa was performed, and the results are tabulated in Table 4. Benzene and ethyl acetate extract showed positive results for the presence of terpenoids, cardiac glycosides, alkaloids, and tannins. Negative results were observed for the presence of steroids, flavonoids, and anthraquinones.

3.3. Identification of Chemical Constituents of the Benzene Extract. Since the benzene extract showed the highest ChE (AChE and BuChE) inhibitory activity, the chemical constituents were further analyzed by TLC and GC-MS for identifying the compounds responsible for the activity exhibited. In classical TLC analysis, spots with chromatographic behavior identical to terpenoids (purple color when exposed to vanillin-sulphuric acid and violet color when sprayed with p-anisaldehyde reagent) were observed for benzene extract (Figure 1). Orange red colored spots were seen in plates treated with Dragendorff’s reagent, which is a positive test for alkaloids (Figure 1) [23, 24]. TLC findings were in agreement with the data of qualitative chemical tests, and the spots characteristic for terpenoids and alkaloids were observed in benzene extract.

A high-resolution mass spectrum equipped with a data system in combination with gas chromatography was used for chemical analysis of benzene extract of G. acerosa. A total of 24 compounds were identified from the benzene extract (Table 5). The extract contained a complex mixture consisting of monoterpene

| S. no. | Solvent extract | 97.56 µg/mL | 195.12 µg/mL | 292.68 µg/mL | 390.24 µg/mL | 487.80 µg/mL | IC50 (µg/mL) |
|-------|----------------|-------------|-------------|-------------|-------------|-------------|-------------|
| 1     | Donepezil      | 98.05 ± 0.23| 98.05 ± 0.12| 98.05 ± 0.30| 98.39 ± 0.34| 98.26 ± 0.23** | 5.0985 ± 0.0046 |
| 2     | Petroleum ether| 9.95 ± 0.65 | 21.93 ± 2.49| 29.20 ± 1.42| 36.31 ± 1.18| 41.36 ± 1.68 | Nil          |
| 3     | Hexane         | NIb         | NIb         | NIb         | NIb         | NIb         | Nil          |
| 4     | Benzene        | 14 ± 1.5    | 40 ± 3.05   | 40 ± 8.08   | 46 ± 3.46   | 54.18 ± 5.65** | 434.61 ± 26.53 |
| 5     | Dichloromethane| NIb         | NIb         | NIb         | NIb         | NIb         | Nil          |
| 6     | Chloroform     | 26.28 ± 0.95| 30.21 ± 0.36| 33.44 ± 0.81| 35.51 ± 0.67| 37.60 ± 1.17 | Nil          |
| 7     | Ethyl acetate  | 39.28 ± 2.02| 42.85 ± 0.68| 46.42 ± 0.68| 50 ± 0.68   | 53.57 ± 9.49* | 444.44 ± 11.63 |
| 8     | Acetone        | 0.19 ± 0.33 | 15.88 ± 1.45| 31.51 ± 2.07| 36.84 ± 0.21| 45.92 ± 0.67 | Nil          |
| 9     | Methanol       | 9.8 ± 0.84  | 9.95 ± 0.34 | 10.02 ± 0.55| 12.37 ± 3.40| 14.82 ± 1.70 | Nil          |
| 10    | Water          | NIb         | NIb         | NIb         | NIb         | NIb         | 6 ± 0.001    | Nil          |

Results were expressed as mean ± SD (n = 3).

bNI: no inhibition.

*P < 0.05.

**P < 0.01.

| S. no. | Solvent extract | 97.56 µg/mL | 195.12 µg/mL | 292.68 µg/mL | 390.24 µg/mL | 487.80 µg/mL | IC50 (µg/mL) |
|-------|----------------|-------------|-------------|-------------|-------------|-------------|-------------|
| 1     | Donepezil      | 67.71 ± 1.09| 85.61 ± 8.50| 85.96 ± 1.84| 96.65 ± 2.64| 91.57 ± 2.41** | 7.266 ± 0.0065 |
| 2     | Petroleum ether| 22.17 ± 3.96| 24.46 ± 2.28| 25.22 ± 4.76| 30.57 ± 1.32| 32.85 ± 4.76 | Nil          |
| 3     | Hexane         | NIb         | NIb         | NIb         | NIb         | NIb         | Nil          |
| 4     | Benzene        | 43.13 ± 7.67| 54.9 ± 9.31 | 56.86 ± 10.19| 70.58 ± 4.76| 78.43 ± 0.00** | 163.01 ± 85.35 |
| 5     | Dichloromethane| NIb         | NIb         | NIb         | NIb         | NIb         | Nil          |
| 6     | Chloroform     | 24.68 ± 8.5 | 39.28 ± 0   | 45.14 ± 2.71| 47.56 ± 0.99| 56.78 ± 2.13** | 375 ± 17.170  |
| 7     | Ethyl acetate  | 15.332 ± 2.03| 23.06 ± 4.75| 30.39 ± 5.71| 32.24 ± 1.58| 37.74 ± 4.19 | Nil          |
| 8     | Acetone        | 12.87 ± 2.5 | 13.61 ± 2.38| 19.51 ± 1.27| 23.21 ± 3.38| 29.11 ± 3.83 | Nil          |
| 9     | Methanol       | NIb         | NIb         | 1.79 ± 1.27 | 2.53 ± 0.004| 16.44 ± 3.43 | Nil          |
| 10    | Water          | NIb         | NIb         | NIb         | NIb         | NIb         | Nil          |

Results were expressed as mean ± SD (n = 3).

bNI: no inhibition.

*P < 0.05.

**P < 0.01.
and sesquiterpene hydrocarbons. The major compounds detected were 5-Amino-2-methoxyphenol; Eicosane; 2-Pentadecanone,6,10,14-trimethyl-; 1,2-Benzenedicarboxylic acid, disoocetyl ester; 9-Octadecenoic acid, 12-(acetyloxy)-, methyl ester, [R-(Z)]; Phytol and Lanosta-7,9(11)-dien-3a,18,20-triol. The anticholinesterase activity observed in the benzene extract might be attributed to the presence of the above-mentioned compounds.

3.4. Computation of Kinetic Parameters. Kinetic studies were performed using IC30 and IC25 of benzene extract of G. acerosa, and the results were tabulated in Table 6. The results suggest that both AChE and BuChE showed maximum enzyme velocity at the concentration of 15 mM. $K_m$, $V_{max}$ and $K_i$ values were determined by plotting Lineweaver-Burk plot. In the case of AChE, an increase in the $K_m$ value (1.729 ± 0.56 nM) was observed without showing any significant change in the $V_{max}$ (0.005 ± 0.0002 nmoles/min/mg of protein) when compared to the control ($K_m$ = 0.8774 nM; $V_{max}$ = 0.0047 nmoles/min/mg of protein), which suggests that the type of inhibition involved might be of competitive type [25]. The $K_i$ value obtained for the extract was 162.94 ± 71.52 μg/mL. Therefore the results suggest that the type of inhibition involved might be uncompetitive [26].

### 4. Discussion

AD is a progressive neurodegenerative disorder characterized by deficit in cholinergic neurotransmission in basal forebrain. ChEIs represent the most promising therapeutic agents for AD type dementia patients, as shown by the clinical studies on the effects of these drugs on cognition (memory and concentration) and behavioral symptoms (apathy and motor agitation) [27]. Many investigations have previously attempted to develop ChEIs for the treatment of AD, either synthetically or via the exploitation of plants and fungi used in traditional medicine, but research into an effective agent from marine algae is still in its infancy. Preliminary screening studies revealed that only crude methanol extract of G. acerosa exhibited antioxidant activity among the various seaweed types used for evaluation [14]. In the present study, we extended this observation to further investigate ChE inhibitory activity using different solvent extracts of G. acerosa in cell-free in vitro assays.

The main finding of the present study was that benzene extract of G. acerosa showed significant dual cholinergic activity; that is, it is active against both AChE and BuChE. Plant extracts, which have dual anti-ChE activity, may be appropriate to patients in moderate stage of AD [27]. Moreover, Hodges [28] demonstrated that inhibition of AChE plays a key role not only in enhancing the cholinergic neurotransmission in the brain but also in reducing the aggregation of β-amyloid the key factor in AD. Donepezil the currently used ChEIs has been reported to activate a-secretase and promote non-amyloidogenic pathway [29]. A recent report also demonstrated that selective BuChE inhibitors reduced amyloid precursor protein processing and Aβ level in vivo and in vitro [30]. These data suggest that the effects may arise from the interaction of these drugs with amyloid cascade, influencing the expression and metabolic
Evidently, the complementary and alternative medicine practice offers therapeutic potential like anticancer, antioxidant, and anti-inflammatory activities either independently or synergistically [34]. Recent findings reveal that terpenoids have potential neuroprotective effects against ischemic and glutamatergic neurotoxicity, 6-hydroxydopamine toxicity, and oxidative stress [33]. Studies on ethanolic extract of Salvia potentillifolia show that the essential oils containing mono- and sesquiterpenoids obtained from them exhibit excellent cholinesterase inhibitory activity in in vitro condition [35]. Shiomi [36] demonstrated the anticholinesterase activity of monoterpenes isolated from fungi. These terpenoids, on the other hand, due to their small molecular size and lipophilicity, readily cross the blood-brain barrier and are effective in the treatment of AD [37]. Hence the observed cholinesterase inhibitory activity of G. acerosa...
extract might be attributed to the presence of the different types of terpenoids.

5. Conclusion

The results obtained from this study clearly indicate that benzene extract of G. acerosa has a powerful ChE inhibitory activity under in vitro condition. The most probable reason for their potential ChEI activity might be related to the presence of terpenoids. The significance of natural ChEIs from G. acerosa will be further characterized, and they will be evaluated for their bioavailability and potential toxicity in vivo.

Conflict of Interests

The authors declare that there is no conflict of interests.

Acknowledgments

P. D. Kasi wishes to thank UGC, India, for offering Major Research Grant (F.No. 36-6/2008 (SR)). A. N. Sayed wishes to thank UGC-MANF for the Junior Research Fellowship provided. The authors gratefully acknowledge the computational and Bioinformatics facility provided by the Alagappa University Bioinformatics Infrastructure Facility (funded by Department of Biotechnology, Government of India; Grant no. BT/BI/25/001/2006).

References

[1] J. L. Cummings, H. V. Vinters, G. M. Cole, and Z. S. Khachaturian, “Alzheimer’s disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities,” Neurology, vol. 51, no. 1, pp. S2–S17, 1998.

[2] R. D. Terry and R. Katzman, “Senile dementia of the Alzheimer type,” Annals of Neurology, vol. 14, no. 5, pp. 497–506, 1983.

[3] M. Irizarry and B. Hyman, “Alzheimer’s disease,” in Principles of Neuropathology, T. Batchlor and M. Cudkowicz, Eds., pp. 69–98, Butterworth-Heinemann, Boston, Mass, USA, 2001.

[4] J. C. Jaén, V. E. Gregor, C. Lee, R. Davis, and M. Emmerling, “Acetylcholinesterase inhibition by fused dihydroquinazoline compounds,” Bioorganic and Medicinal Chemistry Letters, vol. 6, no. 6, pp. 737–742, 1996.

[5] L. S. Schneider, “New therapeutic approaches to Alzheimer’s disease,” Journal of Clinical Psychiatry, vol. 57, supplement 14, pp. 30–36, 1996.

[6] S. Darvesh, R. Walsh, R. Kumar et al., “Inhibition of human cholinesterases by drugs used to treat Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 17, no. 2, pp. 117–126, 2003.

[7] V. Zarotsky, J. J. Sramek, and N. R. Cutler, “Galantamine hydrobromide: an agent for Alzheimer’s disease,” American Journal of Health-System Pharmacy, vol. 60, no. 5, pp. 446–452, 2003.

[8] D. J. McHugh, “A guide to seaweed industry,” FAO Fisheries Technical Paper no. 441, FAO, Rome, Italy, 2003.

[9] K. Hayashi, J. Mori, H. Saito, and T. Hayashi, “Antiviral targets of a chromene derivative from Sargassum micracanthum in the replication of human cytomegalovirus,” Biological and Pharmaceutical Bulletin, vol. 29, no. 9, pp. 1843–1847, 2006.

[10] P. F. Dias, J. M. Siqueira, L. F. Vendruscolo et al., “Antiangiogenic and antitumoral properties of a polysaccharide isolated from the seaweed Sargassum stenophyllum,” Cancer Chemotherapy and Pharmacology, vol. 56, no. 4, pp. 436–446, 2005.

[11] K. Prasad, A. K. Siddhanta, M. Ganesan, B. K. Ramavat, B. Jha, and P. K. Ghosh, “Agars of Gelidiella acerosa of west and southeast coasts of India,” Bioresource Technology, vol. 98, no. 10, pp. 1907–1915, 2007.

[12] G. A. S. Premakumara, W. D. Ratnasooriya, L. M. V. Tillekeratne, A. S. Amarasekare, and A. U. Rahman, “Human sperm motility stimulating activity of a sulfono glycolipid isolated from Sri Lankan marine red alga Gelidiella acerosa,” Asian Journal of Andrology, vol. 3, no. 1, pp. 27–31, 2001.

[13] G. A. S. Premakumara, W. D. Ratnasooriya, and L. M. V. Tillekeratne, “Isolation of a non-steroidal contracegative agent from Sri Lankan marine red alga, Gelidiella acerosa,” Contraception, vol. 54, no. 6, pp. 379–383, 1996.

[14] K. P. Devi, N. Suganthi, P. Kesika, and S. K. Pandian, “Bioprotective properties of seaweeds: in vitro evaluation of antioxidant activity and antimicrobial activity against food borne bacteria in relation to polyphenolic content,” BMC Complementary and Alternative Medicine, vol. 8, article 38, 2008.

[15] R. M. Oza and A. Zaidu, Revised Checklist of Indian Marine Algae, Central Salt and Marine Chemicals Research Institute, Bhavnagar, India, 2003.

[16] V. Krishnamurthy and H. Y. Joshi, A Check List of Indian Marine Algae, Central Salt and Marine Chemicals Research Institute, Bhavnagar, India, 1970.

[17] G. L. Ellman, K. D. Courtney, V. Andres, and R. M. Featherstone, “A new and rapid colorimetric determination of acetylcholinesterase activity,” Biochemical Pharmacology, vol. 7, no. 2, pp. 88–95, 1961.

[18] K. Ingkaninan, C. M. De Best, R. Van Der Heijden et al., “High-performance liquid chromatography with on-line coupled UV, mass spectrometric and biochemical detection for identification of acetylcholinesterase inhibitors from natural products,” Journal of Chromatography A, vol. 872, no. 1–2, pp. 61–73, 2000.

[19] G. E. Trease and W. C. Evans, Pharmacognosy, Bailliere Tindall, London, UK, 13th edition, 1989.

[20] A. Sofowora, Medicinal Plants and Traditional Medicine in Africa, Spectrum Books, Ibadan, Nigeria, 1993.

[21] J. B. Harborne, Phytochemical Methods, Chapman and Hall, London, UK, 1973.

[22] J. B. Harborne, Phytochemical Methods- A Guide to Modern Techniques of Plant Analysis, Chapman and Hall, London, UK, 1980.

[23] H. Wagner, S. Bladt, and E. M. Zygaainski, Plant Drug Analysis- A Thin Layer Chromatography Atlas, Springer, Berlin, Germany, 1984.

[24] S. H. Karmarkar, R. Keshavachandran, and A. Augustin, “Biochemical evaluation of root tubers and in vitro induced callus of adapathiyan (HOLOSTEMMA ADA-KODIEN K. SCHUM.),” Journal of Tropical Agriculture, vol. 39, pp. 108–110, 2001.

[25] T. Benie and M. L. Thieulant, “Interaction of some traditional plant extracts with uterine oestrogen or progesterin receptors,” Phytotherapy Research, vol. 17, no. 7, pp. 756–760, 2003.

[26] J. Balzarini, A. I. Hernández, P. Roche et al., “Non-nucleoside inhibitors of mitochondrial thymidine kinase (TK-2) differentially inhibit the closely related herpes simplex virus type 1 TK
and *Drosophila melanogaster* multifunctional deoxynucleoside kinase; *Molecular Pharmacology*, vol. 63, no. 2, pp. 263–270, 2003.

[27] E. Giacobini, “Drugs that target cholinesterase,” in *Cognitive Enhancing Drugs*, J. J. Buccafusco, Ed., pp. 11–36, Birkhäuser, Basel, Switzerland, 2004.

[28] J. R. Hodges, “Alzheimer’s centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspects,” *Brain*, vol. 129, no. 11, pp. 2811–2822, 2006.

[29] M. Zimmermann, F. Gardoni, E. Marcello et al., “Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines,” *Journal of Neurochemistry*, vol. 90, no. 6, pp. 1489–1499, 2004.

[30] N. H. Greig, T. Utsuki, Q. S. Yu et al., “A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase,” *Current Medical Research and Opinion*, vol. 17, no. 3, pp. 159–165, 2001.

[31] P. K. Mukherjee, V. Kumar, M. Mal, and P. J. Houghton, “Acetylcholinesterase inhibitors from plants,” *Phytomedicine*, vol. 14, no. 4, pp. 289–300, 2007.

[32] F. Menichini, R. Tundis, M. R. Loizzo et al., “Acetylcholinesterase and butyrylcholinesterase inhibition of ethanolic extract and monoterpenes from *Pimpinella anisoides* V. Brig. (Apiaceae),” *Fitoterapia*, vol. 80, no. 5, pp. 297–300, 2009.

[33] H. J. Chang, H. J. Kim, and H. S. Chun, “Quantitative structure-activity relationship (QSAR) for neuroprotective activity of terpenoids,” *Life Sciences*, vol. 80, no. 9, pp. 835–841, 2007.

[34] L. Mu, J. Kou, D. Zhu, and B. Yu, “Comparison of neuroprotective effects of flavonoids, terpenoids, and their combinations from *Ginkgo biloba* on ischemia-reperfusion—injured mice,” *Pharmaceutical Biology*, vol. 45, no. 9, pp. 728–733, 2007.

[35] I. Kivrak, M. E. Duru, M. Öztürk, N. Mercan, M. Harmandar, and G. Topçu, “Antioxidant, anticholinesterase and antimicrobial constituents from the essential oil and ethanol extract of *Salvia potentillifolia*,” *Food Chemistry*, vol. 116, no. 2, pp. 470–479, 2009.

[36] K. Shiomi, “Meroterpenoids with various biological activities produced by fungi,” *Pure and Applied Chemistry*, vol. 71, no. 6, pp. 1059–1064, 1999.

[37] S. U. Savelev, E. J. Okello, and E. K. Perry, “Butyryl- and acetylcholinesterase inhibitory activities in essential oils of *Salvia* species and their constituents,” *Phytotherapy Research*, vol. 18, no. 4, pp. 315–324, 2004.